Table 1.
Demographics | ||
---|---|---|
Age at conception, mean (SD) | 34.8 years (2.9) | |
Duration of disease, mean (SD ) | 65.2 months (54.3) | |
Number of ocrelizumab infusions at conception, mean (SD ) | 1.9 (0.9) | |
Number of previous DMTs, N (%) | 0 | 4 (33.3%) |
1–2 | 4 (33.3%) | |
3 or more | 4 (33.3%) | |
Ocrelizumab exposure, N (%) | Preconception | 13 (92.9%) |
First trimester | 3 (21.4%) | |
Second/third trimester | 0 |